Cargando…
The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients
To evaluate the frequency and clinicopathological features of ROS1 and RET rearrangements in N2 node positive stage IIIA (IIIA-N2) non-small cell lung cancer (NSCLC) patients, we retrospectively screened 204 cases with a tissue microarray (TMA) panel by fluorescent in situ hybridization (FISH), and...
Autores principales: | Fu, Sha, Liang, Ying, Lin, Yong-Bin, Wang, Fang, Huang, Ma-Yan, Zhang, Zi-Chen, Wang, Jing, Cen, Wen-Jian, Shao, Jian-Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408029/ https://www.ncbi.nlm.nih.gov/pubmed/25905642 http://dx.doi.org/10.1371/journal.pone.0124354 |
Ejemplares similares
-
Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021) -
Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer
por: Rogers, Toni-Maree, et al.
Publicado: (2017) -
Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018) -
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023) -
Current management of RET rearranged non-small cell lung cancer
por: Stinchcombe, Thomas E
Publicado: (2020)